Finance

Lists
Outlook: 75.9% bullish·1.8% bearish
Go to analysis
HUM:NYSE
Humana Inc
434,97 US$
+1,68%
(+7,19) 1D
15 ოქტ, 12:48:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HUM...
Open
430,00 US$
High
436,74 US$
Low
429,44 US$
Mkt. cap
52,23 მლრდ.
Avg. vol.
1,35 მლნ.
Volume
316,84 ათ.
Dividend
0,81%
Quarterly dividend
0,88 US$
Ex-dividend date
30 ოქტ. 2026
P/E ratio
41,19
52-wk high
456,50 US$
52-wk low
163,11 US$
EPS
10,56 US$
Beta
0,74
Shares outstanding
120,08 მლნ.
No. of employees
67 ათ.
Open
430,00 US$
High
436,74 US$
Low
429,44 US$
Mkt. cap
52,23 მლრდ.
Avg. vol.
1,35 მლნ.
Volume
316,84 ათ.
Dividend
0,81%
Quarterly dividend
0,88 US$
Ex-dividend date
30 ოქტ. 2026
P/E ratio
41,19
52-wk high
456,50 US$
52-wk low
163,11 US$
EPS
10,56 US$
Beta
0,74
Shares outstanding
120,08 მლნ.
No. of employees
67 ათ.
News stories
From web sources and news partners
Profile
Humana Inc. is an American for-profit health insurance company based in Louisville, Kentucky. In 2024, the company ranked 92 on the Fortune 500 list. It is the fourth largest health insurance provider in the U.S. Wikipedia
About Humana Inc
CEOჯიმ რეხტინი
Employees67,1 ათ.
Founded1961
Headquartersლუისვილი, კენტუკი, ამერიკის შეერთებული შტატები
SectorHealth care provider
Websitehumana.com
Analyst ratings
Based on 23 analysts giving stock ratings to HUM in the past 3 months
Buy
Buy
15
Hold
7
Sell
1
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for HUM in the last 3 months.
Highest
Current 434,97 US$
596,00 US$ (+37,02%)
Average
458,86 US$ (+5,49%)
Lowest
280,00 US$ (-35,63%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andrew Mok CFA
Barclays
Buy
Maintained
582,00 US$
+33,8%
10/14/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
480,00 US$
+10,4%
10/13/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
495,00 US$
+13,8%
10/13/2026
A.J. Rice
UBS
Hold
Reiterated
495,00 US$
+13,8%
10/12/2026
David S Macdonald
Truist Financial
Hold
Maintained
475,00 US$
+9,2%
10/12/2026
John Ransom
Raymond James
Buy
Upgraded
520,00 US$
+19,5%
10/12/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
475,00 US$
+9,2%
10/09/2026
Michael Ha
Robert W. Baird
Buy
Upgraded
596,00 US$
+37%
10/09/2026
Sarah James
Cantor Fitzgerald
Buy
Upgraded
460,00 US$
+5,8%
10/07/2026
Ben Hendrix
RBC Capital
Hold
Maintained
415,00 US$
-4,6%
10/07/2026
Lance Wilkes
Bernstein
Buy
Maintained
425,00 US$
-2,3%
10/05/2026
David Windley
Jefferies
Buy
Maintained
420,00 US$
-3,4%
09/30/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
502,00 US$
+15,4%
09/15/2026
Kevin Fischbeck
Bank of America Securities
Buy
Reiterated
-
-
09/08/2026
Lisa Gill
J.P. Morgan
Hold
Reiterated
393,00 US$
-9,6%
08/10/2026
Erin Wright
Morgan Stanley
Hold
Upgraded
370,00 US$
-14,9%
08/05/2026
Ryan Langston
TD Cowen
Hold
Reiterated
370,00 US$
-14,9%
07/31/2026
Jessica Tassan
Piper Sandler
Buy
Upgraded
463,00 US$
+6,4%
07/30/2026
George Hill
Deutsche Bank
Buy
Maintained
436,00 US$
+0,2%
07/30/2026
Scott Fidel
Goldman Sachs
Sell
Maintained
280,00 US$
-35,6%
07/30/2026
Jason Cassorla
Guggenheim
Buy
Maintained
471,00 US$
+8,3%
07/29/2026
Whit Mayo
Leerink Partners
Buy
Upgraded
513,00 US$
+17,9%
07/30/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
07/30/2026
Parker Snure
Raymond James
Hold
Downgraded
425,00 US$
-2,3%
07/30/2026
Courtney Breen
Bernstein
Buy
Maintained
288,00 US$
-33,8%
05/27/2026
Kevin Caliendo
UBS
Hold
Maintained
262,00 US$
-39,8%
04/30/2026
Last report
29 ივლ. 2026
Fiscal period
Q2 2026
7,61 US$ / 7,00 US$
+8,79%beat
Revenue / Est. (USD)
40,87 მლრდ. / 40,53 მლრდ.
+0,82%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
32,65 მლრდ.
32,52 მლრდ.
39,65 მლრდ.
40,87 მლრდ.
Cost of goods sold
27,99 მლრდ.
28,72 მლრდ.
33,71 მლრდ.
35,37 მლრდ.
Cost of revenue
27,99 მლრდ.
28,72 მლრდ.
33,71 მლრდ.
35,37 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,82 მლრდ.
4,21 მლრდ.
3,93 მლრდ.
3,92 მლრდ.
Operating expense
3,99 მლრდ.
4,38 მლრდ.
4,09 მლრდ.
4,08 მლრდ.
Total operating expenses
31,98 მლრდ.
33,10 მლრდ.
37,80 მლრდ.
39,45 მლრდ.
Operating income
667,00 მლნ.
-583,00 მლნ.
1,85 მლრდ.
1,42 მლრდ.
Other non operating income
-35,00 მლნ.
-53,00 მლნ.
34,00 მლნ.
-211,00 მლნ.
EBT including unusual items
108,00 მლნ.
-1,02 მლრდ.
1,58 მლრდ.
931,00 მლნ.
EBT excluding unusual items
438,00 მლნ.
-796,00 მლნ.
1,68 მლრდ.
987,00 მლნ.
Income tax expense
-86,00 მლნ.
-249,00 მლნ.
395,00 მლნ.
238,00 მლნ.
Effective tax rate
-79,63%
24,29%
25,02%
25,56%
Other operating expenses
-
-
-
-
Net income
195,00 მლნ.
-796,00 მლნ.
1,19 მლრდ.
694,00 მლნ.
Net profit margin
0,60%
-2,45%
2,99%
1,70%
Earnings per share
3,24
-3,96
10,31
7,61
Interest and investment income
-
-
-
-
Interest expense
-168,00 მლნ.
-146,00 მლნ.
-193,00 მლნ.
-197,00 მლნ.
Net interest expenses
-168,00 მლნ.
-146,00 მლნ.
-193,00 მლნ.
-197,00 მლნ.
Depreciation and amortization charges
173,00 მლნ.
164,00 მლნ.
163,00 მლნ.
159,00 მლნ.
EBITDA
871,00 მლნ.
-389,00 მლნ.
2,05 მლრდ.
1,60 მლრდ.
Gain or loss from assets sale
63,00 მლნ.
4,00 მლნ.
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები